Brief: Ironwood Pharmaceuticals Announces FY 2024 Financial Guidance
08/01/2024 11:05
Jan 8 (Reuters) - Ironwood Pharmaceuticals Inc IRWD.O :
* IRONWOOD PHARMACEUTICALS MAINTAINS FY 2023 FINANCIAL
GUIDANCE
AND ANNOUNCES FY 2024 FINANCIAL GUIDANCE
* IRONWOOD PHARMACEUTICALS INC: EXPECTS 2024 ADJUSTED EBITDA
OF
GREATER THAN $150 MILLION -
* IRONWOOD PHARMACEUTICALS INC: EXPECTS HIGH-SINGLE DIGIT
PERCENTAGE LINZESS® EUTRX PRESCRIPTION DEMAND GROWTH IN 2024
Source text for Eikon: ID:nBw1jZTga
Further company coverage: IRWD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ironwood Pharmaceuticals
See all newsBrief: Ironwood Pharmaceuticals Appoints Tammi Gaskins As Chief Executive Officer
Ironwood Pharmaceuticals, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ironwood Q2 revenue rises 33%
Brief: Ironwood Pharmaceuticals Repaid In Full $200 Million 1.5% Convertible Senior Notes Due 2026
Brief: FDA Approves Use Of Linzess In Pediatric Patients Aged 2 & Older With Functional Constipation